

FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICEApplicants Docket Number:  
DEAV2003/0002 US NPApplicants:  
KLINGLER, et al.Serial No.  
10/751,545Filing Date:  
January 5, 2004Title of Invention:  
SELECTIVE MMP-13 INHIBITORS

## CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450, at 703 746-9195, onDate of Deposit July 6, 2004Printed Name of Person Signing Certificate Phyllis Renee McHarrisSignature Phyllis Renee McHarris

Total Number of Pages Sent: 10

Attorney: Raymond S. PARKER, III

Group Art Unit: 1614

Examiner:

TO: Mail Stop Office of Initial Patent Examination's Filing Receipt Corrections  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450Please acknowledge receipt of the below-listed documents for the above Application by return telefax to  
(908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of  
Aventis Pharmaceuticals Inc.

- |  |  |
|--|--|
| <input type="checkbox"/> Amendment, 37 CFR _____               | <input type="checkbox"/> Fee Transmittal   |
| <input type="checkbox"/> Charge deposit account, in duplicate  | <input type="checkbox"/> Petition under 37 CFR _____   |
| <input type="checkbox"/> Extension of Time Petition            | <input checked="" type="checkbox"/> Other <u>Request For Corrected Filing Receipt</u>          |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Copy of Filing Receipt</u>                        |
| <input type="checkbox"/> Maintenance Fee Transmittal           | <input checked="" type="checkbox"/> Other <u>Supplemental Application Data Sheet - 5 pages</u> |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this  
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**KLINGLER, et al.**

Examiner:

Art Unit: 1614

Application No.: **10/751,545**

Filed: **January 5, 2004**

Title: **SELECTIVE MMP-13 INHIBITORS**

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, P. O. Box 1450, Alexandria, VA 22313-1450,  
at (703) 746-9195, on

July 6, 2004  
Date of Deposit  
Phyllis Rose McGinnis  
Signature

**REQUEST FOR CORRECTED FILING RECEIPT**

Mail Stop Office of Initial Patent Examination's Filing Receipt Corrections  
Commissioner of Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Attached is a copy of the official Filing Receipt from the Patent and Trademark Office in the  
above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

There is an error in that the First named inventor's name is misspelled. It should appear as  
follows: **Otmar KLINGLER.**

There is also an error in the order of inventors. Please list the inventors in the following  
order:


**Otmar KLINGLER**  
**Reinhard KIRSCH**  
**Joerg HABERMANN**  
**Klaus-Ulrich WEITHMANN**  
**Christian ENGEL**  
**Bernard PIRARD**

Also, a supplemental application data sheet is enclosed.

The Commissioner is hereby authorized to charge any fees which are required by this paper to Deposit Account 18-1982.

Respectfully submitted,

July 6, 2004

  
Raymond S. Parker, III, Ph.D., Reg. No. 34,893  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-5674  
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0002 US NP



Early Publication Request: No

**Title**

Selective MMP-13 inhibitors

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).